文献速递外周动脉疾病

人脱细胞血管用于慢性肢体威胁性缺血患者下肢动脉旁路移植的结局

Outcomes of lower extremity arterial bypass using the Human Acellular Vessel in patients with chronic limb-threatening ischemia.
PubMed 文献 · J Vasc Surg · 2023-10-26

该研究基于美国食品药品监督管理局(FDA)扩展可及计划,纳入29例无自体静脉可用的慢性肢体威胁性缺血(CLTI)患者,使用人脱细胞血管(HAV)作为旁路 conduit。技术成功率100%,30天死亡率7%,中位随访9.3个月保肢率86%,9个月一期和二期通畅率分别为59%和71%。

要点

  • HAV在无自体静脉可用的CLTI患者中技术成功率达100%,30天死亡率为7%。
  • 中位随访9.3个月保肢率为86%(25/29),9个月一期和二期通畅率分别为59%和71%。
  • 16次再干预恢复二期通畅,其中15次(94%)成功。

核心结论

  • HAV在无自体移植选项的肢体威胁性缺血复杂队列中作为动脉旁路 conduit 表现出短期至中期安全性和有效性。
  • 该FDA扩展可及计划经验提供真实世界数据,为HAV的监管审议和未来试验提供信息,包括研究该血管在较轻慢性肢体缺血病例中作为一线旁路 conduit。

研究设计与样本

  • FDA支持的中间规模、单中心研究,在扩展可及计划下纳入晚期CLTI且自体 conduit 不足或缺失的患者。
  • 2021年3月至2023年7月间,29例患者(20例男性;平均年龄71±11岁)使用HAV作为旁路 conduit 接受保肢手术。

主要发现

  • 大多数患者为晚期CLTI(Rutherford 5/6级占72%;伤口、缺血和足部感染3/4期占83%),97%的患者此前同侧肢体血运重建失败。
  • 24例患者(83%)将两个HAV缝合以达到所需旁路长度;旁路至胫动脉23例(79%),至腘动脉6例(21%)。
  • 技术成功率为100%,30天死亡率为7%(2例患者)。
  • 随访率100%(中位9.3个月),保肢率为86%(25/29例患者)。
  • 为恢复二期通畅行16次再干预,其中15次(94%)成功;HAV 9个月一期和二期通畅率分别为59%和71%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Patients with chronic limb-threatening ischemia (CLTI) and no great saphenous vein to use as a conduit for arterial bypass have a high risk for amputation despite advances in medical and endovascular therapies. This report presents findings from a U.S. Food and Drug Administration (FDA) supported study of the Human Acellular Vessel (HAV) (Humacyte Inc.) used as a conduit for arterial bypass in patients with CLTI and inadequate or absent autologous conduit. METHODS: The HAV is a 6-mm, 40-cm vessel created from human vascular smooth muscle cells seeded onto a polyglycolic acid scaffold pulsed in a bioreactor for 8 weeks as cells proliferate and the scaffold dissolves. The resultant vessel is decellularized, creating a nonimmunogenic conduit composed of collagen, elastin, and extracellular matrix. The FDA issued an Investigational New Drug for an intermediate-sized, single-center study of the HAV under the agency's Expanded Access Program in patients with advanced CLTI and inadequate or absent autologous conduit. Technical results and clinical outcomes were analyzed and reported. RESULTS: Between March 2021 and July 2023, 29 patients (20 males; mean age, 71 ± 11 years) underwent limb salvage operation using the HAV as a bypass conduit. Most patients had advanced CLTI (Rutherford class 5/6 in 72%; wound, ischemia, and foot infection stage 3/4 in 83%), and 97% had previously failed revascularization(s) of the extremity. Two HAVs were sewn together to attain the needed bypass length in 24 patients (83%). Bypasses were to tibial arteries in 23 patients (79%) and to the popliteal artery in 6 (21%). Technical success was 100%, and the 30-day mortality rate was 7% (2 patients). With 100% follow-up (median, 9.3 months), the limb salvage rate was 86% (25/29 patients). There were 16 reinterventions to restore secondary patency, of which 15 (94%) were successful. Primary and secondary patency of the HAV at 9 months were 59% and 71%, respectively. CONCLUSIONS: The HAV has demonstrated short- to intermediate-term safety and efficacy as an arterial bypass conduit in a complex cohort of patients with limb-threatening ischemia and no autologous options. This experience using the FDA's Expanded Access Program provides real-world data to inform regulatory deliberations and future trials of the HAV, including the study of the vessel as a first-line bypass conduit in less severe cases of chronic limb ischemia.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Cifuentes S, Sen I, Shuja F, et al. Outcomes of lower extremity arterial bypass using the Human Acellular Vessel in patients with chronic limb-threatening ischemia. J Vasc Surg. 2023. PMID: 37890643. doi:10.1016/j.jvs.2023.10.040

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。